TY - JOUR
T1 - Modulators of inflammation in Bronchopulmonary Dysplasia
AU - Savani, Rashmin C
N1 - Funding Information:
The author is mindful that this review is not intended to be all encompassing and any omission of work that would be relevant to the topic of this review is not intentional. The author is a co-founder of Eravon Therapeutics, Inc. that is focused on RHAMM-HA-based therapeutics. Funding for the studies described that were conducted in the Savani laboratory was from NIH R01 awards HL62868, HL62472 and HL093535, and U01 award HL075900. Additional funding was obtained from the William Buchanan Chair in Pediatrics and a Children's Hospital Foundation Dallas grant (#137).
Funding Information:
The author is mindful that this review is not intended to be all encompassing and any omission of work that would be relevant to the topic of this review is not intentional. The author is a co-founder of Eravon Therapeutics, Inc. that is focused on RHAMM-HA-based therapeutics. Funding for the studies described that were conducted in the Savani laboratory was from NIH R01 awards HL62868, HL62472 and HL093535, and U01 award HL075900. Additional funding was obtained from the William Buchanan Chair in Pediatrics and a Children's Hospital Foundation Dallas grant ( #137 ).
Publisher Copyright:
© 2018
PY - 2018/11
Y1 - 2018/11
N2 - Over 50 years after its first description, Bronchopulmonary Dysplasia (BPD) remains a devastating pulmonary complication in preterm infants with respiratory failure and develops in 30–50% of infants less than 1000-gram birth weight. It is thought to involve ventilator- and oxygen-induced damage to an immature lung that results in an inflammatory response and ends in aberrant lung development with dysregulated angiogenesis and alveolarization. Significant morbidity and mortality are associated with this most common chronic lung disease of childhood. Thus, any therapies that decrease the incidence or severity of this condition would have significant impact on morbidity, mortality, human costs, and healthcare expenditure. It is clear that an inflammatory response and the elaboration of growth factors and cytokines are associated with the development of BPD. Numerous approaches to control the inflammatory process leading to the development of BPD have been attempted. This review will examine the anti-inflammatory approaches that are established or hold promise for the prevention or treatment of BPD.
AB - Over 50 years after its first description, Bronchopulmonary Dysplasia (BPD) remains a devastating pulmonary complication in preterm infants with respiratory failure and develops in 30–50% of infants less than 1000-gram birth weight. It is thought to involve ventilator- and oxygen-induced damage to an immature lung that results in an inflammatory response and ends in aberrant lung development with dysregulated angiogenesis and alveolarization. Significant morbidity and mortality are associated with this most common chronic lung disease of childhood. Thus, any therapies that decrease the incidence or severity of this condition would have significant impact on morbidity, mortality, human costs, and healthcare expenditure. It is clear that an inflammatory response and the elaboration of growth factors and cytokines are associated with the development of BPD. Numerous approaches to control the inflammatory process leading to the development of BPD have been attempted. This review will examine the anti-inflammatory approaches that are established or hold promise for the prevention or treatment of BPD.
UR - http://www.scopus.com/inward/record.url?scp=85056706341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056706341&partnerID=8YFLogxK
U2 - 10.1053/j.semperi.2018.09.009
DO - 10.1053/j.semperi.2018.09.009
M3 - Review article
C2 - 30446300
AN - SCOPUS:85056706341
SN - 0146-0005
VL - 42
SP - 459
EP - 470
JO - Seminars in Perinatology
JF - Seminars in Perinatology
IS - 7
ER -